QURT
Quarta-Rad, Inc.0.6500
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
10.33MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Quarta-Rad's Q2 FY2025 revenue climbed 132% y/y to $67.3K, driven by Sellavir's $65K in AI consulting services to related parties, while Quarta-Rad's device sales dropped 92% y/y to $2.3K amid supply constraints from the Russian invasion of Ukraine. Gross profit rose to $37.7K, but operating expenses jumped 47% y/y to $124.3K, fueled by $55.7K in stock-based compensation, yielding an operating loss of $86.6K—up 17% y/y—versus a net loss of $72.1K after $13.7K foreign currency gains. YTD revenue doubled 96% y/y to $100.2K, narrowing net loss to $149.5K from $154K, with diluted EPS steady at $(0.01) on 15.9M shares. Cash dwindled to $29.6K after $33.5K operating outflow, no debt but $250K liabilities mostly related-party payables; a $199K note receivable transfer settled obligations. Sellavir's CenterEye AI platform shows early Japan traction. Yet competition in AI call center software poses adoption risks.
10-Q
Q1 FY2025 results
Quarta-Rad posted Q1 FY2025 net sales of $32.9K, up 49.2% y/y from $22.0K, driven by $30.0K from Sellavir's AI services while Quarta-Rad's device sales fell 86.9% y/y to $2.9K amid supply constraints. Gross loss narrowed to $1.4K from $11.8K profit, with operating loss widening to $89.9K (up 43.8% y/y) on $37.1K stock-based compensation, yet net loss improved 15.5% y/y to $77.4K, or $0.00 per diluted share on 15.8M shares. Cash dipped q/q to $49.8K after $13.3K operating outflow, with no capex so free cash flow matched; related-party notes receivable stand at $403.5K, but a $382K working capital deficit persists. Sellavir's CenterEye platform gained Japan traction. Geopolitical risks from the Russian invasion of Ukraine continue to crimp device inventory.
10-K
FY2024 results
Quarta-Rad's FY2024 revenue plunged 79% to $106,797 from $508,316 in 2023, driven by inventory constraints in Quarta-Rad's detection devices and deferred recognition in Sellavir's AI services, yielding a net loss of $216,755 versus prior profit. Quarta-Rad sales fell 79% to $66,797 amid reduced purchases, while Sellavir dropped 79% to $40,000 but pivoted to call center AI innovation. Operating expenses rose 26% to $246,549, fueled by contractor costs, eroding gross profit to $39,685. Cash dwindled to $63,021 with a $260,907 working capital deficit, yet related-party notes provided $46,812 in interest income. No quarterly breakdowns disclosed. Management eyes capital raises and partnerships to fund Sellavir's CenterEye platform. Geopolitical tensions could further disrupt supply chains.
10-Q
Q3 FY2024 results
Quarta-Rad's Q3 FY2024 results show revenue plunging 70% y/y to $18,697, driven by an 86% drop in Quarta-Rad sales to $8,697 amid Russian supply constraints, while Sellavir added $10,000 from a new licensing deal. Gross profit swung to $13,503 from a slim $2,930 last year, but operating expenses climbed 9% to $58,324, yielding a narrower operating loss of $48,821 versus $50,649. Net loss shrank to $2,609, cushioned by a $33,300 foreign currency gain and investment swings, though YTD net loss widened to $156,604 on 81% revenue decline to $69,783 and a $110,561 realized investment loss; EPS holds at -$0.01 with 15.7M shares. Cash dipped to $50,281, with $87,864 used in operations offset by $65,520 from security sales, and no debt but $384,530 in related-party liabilities. Post-quarter, a spin-off of operations is under exploration. Russian sanctions continue to crimp inventory flows.
IPO
Website
Sector
Industry
ARAY
Accuray Incorporated
1.02-0.03
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
IRMD
iRadimed Corporation
96.87-0.15
MIR
Mirion Technologies, Inc.
24.15-0.17
QDEL
QuidelOrtho Corporation
28.88-0.18
QTIH
QT Imaging Holdings, Inc.
6.10-0.02
QTRX
Quanterix Corporation
7.36-0.05
SRTS
Sensus Healthcare, Inc.
3.80+0.11
TDY
Teledyne Technologies Incorpora
506.54-7.75
UCLE
US Nuclear Corp.
0.04-0.06